4
Shared Docs
4
Same-Page
4 / 4
Mentions
ffects that different human genetic backgrounds and mutations may have on AD pathologies in vivo. Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebneth A, Hardy J, Leroy K, Brion JP, Vander
this type of approach could prove to be very useful for screening, stratifying, and enrolling subjects for drug trials. Desikan RS, Fan CC, Wang Y, Schork Al, Cabral HI, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer JB, Karow DS, Kauppi K, Witoelar A, Karch CM, Bonham LW, Yokoya
effects that different human genetic backgrounds and mutations may have on AD pathologies in vivo. Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebneth A, Hardy J, Leroy K, Brion JP, Vander
this type of approach could prove to be very useful for screening, stratifying, and enrolling subjects for drug trials. Desikan RS, Fan CC, Wang Y, Schork Al, Cabral HJ, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer 1B, Karow DS, Kauppi K, Witoelar A, Karch CM, Bonham LW, Yokoya
ffects that different human genetic backgrounds and mutations may have on AD pathologies in vivo. Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebneth A, Hardy J, Leroy K, Brion JP, Vander
proach could prove to be very useful for screening, stratifying, and enrolling subjects for drug trials. EFTA00449356 Desikan RS, Fan CC, Wang Y, Schork Al, Cabral HI, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer JB, Karow DS, Kauppi K, Witoelar A, Karch CM, Bonham LW, Yokoya
effects that different human genetic backgrounds and mutations may have on AD pathologies in vivo. Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck 5, Bonnefont 1, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebneth A, Hardy J, Leroy K, Brion JP, Vanderh
this type of approach could prove to be very useful for screening, stratifying, and enrolling subjects for drug trials. Desikon RS, Fan CC, Wang Y, Schork Al, Cabral Hi, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer .1B, Karow DS, Kouppi K, Witoelar A, Korch CM, Bonham LW Yokoya
Entities connected to both Ando K and Schork Al
Ebneth A
ORGANIZATIONKukull WA
LOCATIONWang J
PERSONLiu et al
PERSONKitamura
ORGANIZATIONDavid Holtzman
PERSONFiers M
ORGANIZATIONSnellinx
ORGANIZATION
Edward Snowden
PERSONCorthout N
ORGANIZATIONOmodho L
ORGANIZATIONRadaelli E
ORGANIZATIONTesseur
ORGANIZATIONHess CP
ORGANIZATIONZhao N
PERSONMayeux
ORGANIZATIONHoltzman DM
PERSON
J Neurosci
PERSONEspuny-Camacho
PERSONArranz
PERSON